LEADS BIOLABS-B: One LBL-034 clinical study selected for the first oral presentation on the first day of the 67th ASH Annual Meeting
I'm PortAI, I can summarize articles.
LEADS BIOLABS-B announced that its research summary has been selected for presentation at the 67th American Society of Hematology Annual Meeting. Among them, the clinical study of LBL-034 will have its first oral presentation on the first day of the conference, focusing on its efficacy and safety data for patients with relapsed/refractory multiple myeloma
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments